Research & Education

Malignant Pleural Mesothelioma - Multidisciplinary Treatment Update

Wednesday July 27, 2016 9:00PM EDT

Malignant Pleural Mesothelioma (MPM) remains one of the most intractable malignancies with current overall survival (OS) of about 12 months in unresectable advanced stages. Multimodality therapy in resectable patients yields median OS of 17-25 months. Recently, the field has made several advances due to novel discoveries and initiatives in epidemiology, screening/detection and treatment.

Radiation Oncology Highlights: ASCO 2016

July 7, 2016 6:00PM CEST

This program will review radiation therapy for lung cancer highlights from the recent 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The focus of the presentations are upon the most relevant data and reports that impact current standards of care in the radiotherapeutic management of non-small cell lung cancer (NSCLC).

Treatment of Patients With EGFR-Mutant NSCLC

July 5, 2016 at 6:00 PM CEST

Patients harboring EGFR mutations represent a subgroup of non-small cell lung cancer (NSCLC) with high sensitivity to EGFR-Tyrosine kinase inhibitors. Many agents are currently available in clinical practice with small differences in terms of efficacy and toxicity profile.

Implementing and Integrating a CT Screening and Smoking Cessation Program

June 30, 2016 9:00PM EDT

"Implementing smoking cessation in lung cancer screening settings: Opportunities and Challenges"

IASLC Lung Cancer Grand Rounds: Advances in Treatment of Lung Cancer - 2016 Update

June 28, 2016 at 9:00 PM EDT

This live session of IASLC Lung Cancer Grand Rounds features Dr. Mark Socinski. Dr. Socinski will highlight recent data in lung cancer, presented during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The program will focus on scientific and clinical progress most likely to impact the current management of patients with lung cancer.

IASLC European Webinar Series - 2015/2016 - Optimal Utilization of Anti-Angiogenesis Therapy for NSCLC

June 23, 2016 at 7:00PM Central European Summer Time

This presentation will provide an overview of the concept of angiogenesis and antiangiogenesis in NSCLC as one of the "hallmarks of cancer". Available data with bevacizumab - containing regimens in patients with advanced non squamous NSCLC - will be briefly reviewed.

Update from 2016 Radiation Oncology Meetings

Thursday May 26, 2016 6:00PM Central European Summer Time

This program will review radiation therapy for lung cancer highlights from the recent 2016 European Lung Cancer Conference (ELCC) and European Society for Radiotherapy & Oncology (ESTRO) meetings.

IASLC European Webinar Series - 2015/2016 - Management of TKI Resistance in NSCLC

Wednesday, May 11, 2016 at 7 p.m. Central European Summer Time

Although patients with oncogenic-addicted NSCLC respond to targeted therapies, invariably all became refractory to the treatment as a consequence of acquired resistance. Identification of molecular mechanisms responsible for therapy failure is of crucial relevance and many new agents and strategies are currently under development.

IASLC European Webinar Series - 2015/2016 - Treatment of ALK-Positive NSCLC

Tuesday, April 19, 2016 - 7 p.m. Central European Standard Time - Recording Available

EML4 ALK inversion produces a new fusion protein kinase receptor active in 5-7% of lung adenocarcinomas. A number of small, oral molecules ALK TKI inhibitors have been developed recently. These agents have been shown to highly active and capable of substantial control of ALK driven disease. In this online educational presentation, we examine these data from recent clinical trials and address the role of ALK TKI inhibitors in current treatment paradigms.

New Frontiers in the Management of Lung Cancer

Launch: April 18, 2016; Termination: April 17, 2019